The design and user-testing of a question prompt list for attention-deficit/ hyperactivity disorder

BMJ Open

Volumn 4, Issue 12, 2014, Pages

  Ahmed, Rana ^a   Raynor, David K ^b   McCaffery, Kirsten J ^c   Aslani, Parisa ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; ASSESSMENT OF HUMANS; ATTENTION DEFICIT DISORDER; BOOK; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; GENDER; HEALTH CARE PERSONNEL; HUMAN; INTERVIEW; MALE; MEDICAL DECISION MAKING; NORMAL HUMAN; PRACTICE GUIDELINE; QUESTION PROMPT LIST; QUESTIONNAIRE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAREGIVER; COHORT ANALYSIS; DECISION MAKING; DOCTOR PATIENT RELATION; INTERPERSONAL COMMUNICATION; MIDDLE AGED; PUBLICATION;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAREGIVERS; COHORT STUDIES; COMMUNICATION; DECISION MAKING; FEMALE; HUMANS; MALE; MIDDLE AGED; PAMPHLETS; PHYSICIAN-PATIENT RELATIONS; SURVEYS AND QUESTIONNAIRES;

EID: 84920749651     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006585     Document Type: Article

References (50)

1. Warikoo N, Faraone SV. Background, clinical features and treatment of attention deficit hyperactivity disorder in children. Expert Opin Pharmacother 2013;14:1885-906.
2. Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006;67(Suppl 8):7-12.
3. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999;46:1234-42.
4. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med 2002;53:113-31.
5. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008;28:S46-53.
6. del Campo N, Chamberlain SR, Sahakian BJ, et al. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;69:e145-57.
7. Pescosolido BA, Jensen PS, Martin JK, et al . Public knowledge and assessment of child mental health problems: findings from the national stigma study-children. J Am Acad Child Adolesc Psychiatry 2008;47:339-49.
8. Mayes R, Bagwell C, Erkulwater J. ADHD and the rise in stimulant use among children. Harv Rev Psychiatry 2008;16:151-66.
9. Radomsky M. Kids on speed? [television broadcast]. Sydney: Australian Broadcasting Corporation, 2014.
10. Boyle CA, Boulet S, Schieve LA, et al. Trends in the prevalence of developmental disabilities in US children, 1997 -2008. Pediatrics 2011;127:1034-42.
11. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 2012;344:e3502.
12. Frances A. The first draft of DSM-V. BMJ 2010;340:c1168.
13. Ghanizadeh A. Agreement between Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and the proposed DSM-V attention deficit hyperactivity disorder diagnostic criteria: an exploratory study. Compr Psychiatry 2013;54:7-10.
14. Batstra L, Frances A. DSM-5 further inflates attention deficit hyperactivity disorder. J Nerv Ment Dis 2012;200:486-8.
15. Brinkman WB, Sherman SN, Zmitrovich AR, et al. Parental angst making and revisiting decisions about treatment of attention-deficit/ hyperactivity disorder. Pediatrics 2009;124:580-9.
16. Hansen DL, Hansen EH. Caught in a balancing act: Parents' dilemmas regarding their ADHD child's treatment with stimulant medication. Qual Health Res 2006;16:1267-85.
17. Ahmed R, Borst JM, Yong CW, et al. Do parents of children with attention-deficit/hyperactivity disorder (ADHD) receive adequate information about the disorder and its treatments? A qualitative investigation. Patient Prefer Adherence 2014;8:661-70.
18. Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res 2013;13:791-815.
19. Narayan S, Hay J. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res 2004;4:625-34.
20. Chacko A, Newcorn JH, Feirsen N, et al. Improving medication adherence in chronic pediatric health conditions: a focus on ADHD in youth. Curr Pharm Des 2010;16:2416-23.
21. Clay D, Farris K, McCarthy AM, et al. Family perceptions of medication administration at school: errors, risk factors, and consequences. J Sch Nurs 2008;24:95-102.
22. Ahmed R, Borst J, Wei YC, et al. Parents' perspectives about factors influencing adherence to pharmacotherapy for ADHD. J Atten Disord 2013. doi:10.1177/1087054713499231.
23. Ahmed R, McCaffery KJ, Aslani P. Factors influencing parental decision making about stimulant treatment for attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2013;23:163-78.
24. Sciberras E, Iyer S, Efron D, et al. Information needs of parents of children with attention-deficit/hyperactivity disorder. Clin Pediatr 2010;49:150-7.
25. Hummelinck A, Pollock K. Parents' information needs about the treatment of their chronically ill child: a qualitative study. Patient Educ Couns 2006;62:228-34.
26. Coulter A, Entwistle V, Gilbert D. Sharing decisions with patients: is the information good enough? BMJ 1999;318:318-22.
27. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 1999;49:651-61.
28. Joosten EAG, DeFuentes-Merillas L, de Weert GH, et al. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008;77:219-26.
29. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997;44:681-92.
30. Drotar DC, Crawford P, Bonner M. Collaborative decision-making and promoting treatment adherence in pediatric chronic illness. Patient Intell 2010;2:1-7.
31. Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22
32. rd edn. Toronto: CADDRA, 2011.
33. National Health and Medical Research Council. Clinical practice points on the diagnosis, assessment and management of attention deficit hyperactivity disorder in children and adolescents . Canberra, Australia: Australian Government, 2012.
34. Fiks AG, Hughes CC, Gafen A, et al. Contrasting parents' and pediatricians' perspectives on shared decision-making in ADHD. Pediatrics 2011;127:e188-96.
35. Clayton JM, Butow PN, Tattersall MH, et al. Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol 2007;25:715-23.
36. Clayton J, Butow P, Tattersall M, et al. Asking questions can help: development and preliminary evaluation of a question prompt list for palliative care patients. Br J Cancer 2003;89:2069-77.
37. Langbecker D, Janda M, Yates P. Development and piloting of a brain tumour-specific question prompt list. Eur J Cancer Care 2012;21:517-26.
38. Centers for Disease Control and Prevention. Simply put: a guide for creating easy-to-understand materials. Atlanta, Georgia: Centers for Disease Control and Prevention, 2009.
39. Jay E, Aslani P, Raynor D. User testing of consumer medicine information in Australia. Health Educ J 2011;70:420-7. doi:10.1177/0017896910376131
40. Sless D, Shrensky R. Writing about medicines for people: usability guidelines for consumer product information: Australian Self-Medication Industry, Incorporated. 2007.
41. Knapp P, Raynor DK, Silcock J, et al. Performance-based readability testing of participant materials for a phase I trial: TGN1412. J Med Ethics 2009;35:573-8.
42. Knapp P, Raynor DK, Silcock J, et al. Can user testing of a clinical trial patient information sheet make it fit-for-purpose? A randomized controlled trial. BMC Med 2011;9:89.
43. Knapp P, Raynor DK, Silcock J, et al. Performance-based readability testing of participant information for a Phase 3 IVF trial. Trials 2009;10:79.
44. Knapp P, Wanklyn P, Raynor DK, et al. Developing and testing a patient information booklet for thrombolysis used in acute stroke. Int J Pharm Pract 2010;18:362-9.
45. Harris E, Enright D. New words for cautionary and advisory labels make them easily understood. Pharm J 2011;286:278-9.
46. Dale E, Chall JS. A formula for predicting readability. Educ Res Bull 1948;27:11-28.
47. Laughlin GHM. SMOG grading-a new readability formula. J Read 1969;12:639-46.
48. Raynor DK. User testing in developing patient medication information in Europe. Res Social Adm Pharm 2013;9:640-5.
49. Raynor DK, Knapp P, Silcock J, et al. "User-testing" as a method for testing the fitness-for-purpose of written medicine information. Patient Educ Couns 2011;83:404-10.
50. Kelly M. The role of theory in qualitative health research. Fam Pract 2010;27:285-90.\